7 Best Vaccine Manufacturing Pharma Company 2024 each specialising in vaccines, generics, nutraceuticals, oncology/cancer, penicillin, cephalosporins, non-beta-lactam, injectables, WFI, parentals, medical device, and ophthalmic. Additionally, it boasts the vital YKTM (Yoweri Kaguta Tibuhaburwa Museveni) GLP Biotech Laboratories, which covers the groundbreaking components of cancer research, QA/QC, drug discovery, gene therapy, cell therapy, mRNA therapeutics, vaccines, biosimilars, and biologics. Crucially, the facility has the ability to manufacture biological drugs, cytokines, therapeutic protein, peptides, and monoclonal antibodies. It is this part of the facility that cost more than $1 billion, and that which makes the facility so one-of-its-kind and game-changing. Dei BioPharma Ltd’s manufacturing plant produces high-quality, affordable medicines to cure a variety of illnesses, utilising the latest technologies such as mRNA and Cas9 to make a difference to the lives of millions of families across Africa. This includes the development of a drug to treat malaria, which contains natural herbs and can cure the disease in around three days. Dr Magoola has advised how, just as Uganda discovered malaria compounds, it is expected that, with the work of Dei BioPharma, the country will become the very centre of excellence for drug discovery using plants and herbs in the world, since 70% of all biodiversity is found in the region. In 2022, experts at the World Health Organization (WHO) commended the company for its manufacturing facility, identifying it as a base for Africa to effectively respond to COVID-19 and other viruses. Leading the team, Prof. Joseph Okeibunor says, “This massive investment will provide immediate employment for Africa and lead research and manufacturing in traditional medicines.” “We’ve been called dreamers, inventors, rebels, risk takers, pioneers, geeks, and pathfinders. We embrace those labels because in many ways, they’re true. We dream big. We invent bigger. And, most importantly, we often do what many thought was impossible.” It was in May this year that Dei BioPharma Ltd was granted the landmark license to begin manufacturing drugs at its facility by the National Drug Authority (NDA), which represents a significant achievement for the company. Not only is Dei BioPharma Ltd providing revolutionary healthcare products for its home region, but it also branching out globally. Having already filed a patent for its malaria cure in the USA, Dr Magoola shares how big pharma is very interested in further collaboration with Dei BioPharma Ltd, particularly with how antimicrobial drugs resistance is a real problem that is pushing the world to rapidly discover new drugs. Dr Magoola states, “Our competitors are not in Africa but the developed world. Even in the developed world, our competitors are happily collaborating with us! Because our technologies are not only changing Africa, but the globe!” It is already clear to see the dedication of Dei BioPharma Ltd – and Dei Group as a whole – towards the health and wellbeing of both the people of Africa and around the world. This extends further to its Corporate Social Responsibility (CSR), which remains focused on helping those who are in need and living in underprivileged communities, in the areas of health, education, drinking water, and sanitisation. Dei BioPharma Ltd utilises its own internal resources, such as research, marketing, financial, human resources, and products to maximise its ability to help, have an impact, and increase the reach of its CSR efforts. Also, within this commitment, the company’s EHS (Environmental, Health, and Safety) Policy means it maintains a safe, clean, and healthy working environment for its employees and served communities. By adhering to the highest standards in its plant design, equipment selection, maintenance, and operations, Dei BioPharma Ltd’s EHS Policy remains at its core. Also, it has established an ISO14001:2015 compliant Environmental Management System and ISO 45001:2018 compliant Occupational Health and Safety Management System at its facility, further underscoring its dedication. Dei BioPharma facilities have been built to meet the most stringent global Current Good Manufacturing Practices (cGMP) including US FDA and EU EMA and WHO standards among others. Ultimately, it is highly evident how Dei BioPharma Ltd has come to be recognised as Best Vaccine Manufacturing Pharma Company 2024 within the African Excellence Awards, with its outstanding vaccine offering, which is made possible through cuttingedge facilities and expert staff. It is an organisation that goes above and beyond, extending its work further to perform crucial, trailblazing medical research and manufacture life-saving medicines. The company has solidified its position on the global map as an industry leader, with the vital role it is playing within our healthcare industry today. Considering all this, we at MEA Markets magazine simply cannot wait to see what this best-inclass organisation does next. Company: Dei BioPharma Ltd Contact: Dr Matthias Magoola Email: [email protected] Website: www.deibiopharma.com / www. deigroupinternational.com
RkJQdWJsaXNoZXIy MTUyMDQwMA==